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LETTER TO THE EDITOR
Total bilirubin is a good discriminator between benign and
malignant biliary strictures
Sir,
We read with interest the article by Garcea et al.1 about differ-
entiating between benign and malignant biliary strictures in
patients with obstructive jaundice. From 2006 to 2010, we pro-
spectively evaluated serum biochemistry and carbohydrate
antigen 19-9 (CA19-9) values for the same purpose in 72 patients
with suspected malignancy of the common bile duct. Serum bio-
chemistry, liver ultrasonography, computed tomography and
endoscopic retrograde cholangiopancreatography were under-
taken at study entry.
A total of 53 (73.6%) strictures were determined by brush
cytology or surgical biopsy to be malignant and 19 (26.4%) to be
benign. Significant differences between patients with, respectively,
malignant and benign strictures were apparent in levels of:
total bilirubin (12.6 mg/dl vs. 4.5 mg/dl; P < 0.001); alanine
aminotransferase (227 IU/l vs. 101 IU/l; P = 0.002); aspartate
aminotransferase (188 IU/l vs. 101 IU/l; P < 0.001); alkaline phos-
phatase (425 IU/l vs. 257 IU/l; P = 0.024), and CA19-9
(1427 IU/ml vs. 655 IU/ml; P = 0.002). Only bilirubin was found
to be independently associated with malignancy on multivariate
logistic regression analysis (odds ratio = 0.778, 95% confidence
interval 0.663–0.993; P = 0.002). Similarly, in receiver operating
characteristic (ROC) curve analyses, bilirubin offered the best
diagnostic accuracy (c-statistic: 0.822). The optimal cut-off was
5.15 mg/dl (87.5 mmol/l), offering sensitivity of 82.4% and speci-
ficity 77.8%. Using a bilirubin cut-off value of 5.15 mg/dl, four of
five patients were categorized correctly.
We and others2–5 have confirmed the findings of Garcea and
colleagues1 that serum bilirubin is useful in predicting malignant
strictures, although cut-off levels vary (75–145 mmol/l) as a result
of differences in the clinical characteristics of the patients
included in each study.
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